🚀 VC round data is live in beta, check it out!
Adimmune Valuation Multiples
Discover revenue and EBITDA valuation multiples for Adimmune and similar public comparables like Sensorion, Milestone Pharmaceuticals, Acepodia, Nkarta and more.
Adimmune Overview
About Adimmune
Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions.
Founded
1965
HQ
Employees
518
Website
Sectors
Financials (FY)
EV
$261M
Adimmune Financials
Adimmune reported last fiscal year revenue of $45M and negative EBITDA of ($3M).
In the same fiscal year, Adimmune generated $9M in gross profit, ($3M) in EBITDA losses, and had net loss of ($8M).
Adimmune P&L
In the most recent fiscal year, Adimmune reported revenue of $45M and EBITDA of ($3M).
Adimmune expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $45M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $9M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (23%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (17%) | XXX | XXX | XXX |
| Net Debt | — | — | $18M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Adimmune Stock Performance
Adimmune has current market cap of $242M, and enterprise value of $261M.
Market Cap Evolution
Adimmune's stock price is $0.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $261M | $242M | -2.4% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAdimmune Valuation Multiples
Adimmune trades at 5.9x EV/Revenue multiple, and (97.9x) EV/EBITDA.
Adimmune Financial Valuation Multiples
As of April 21, 2026, Adimmune has market cap of $242M and EV of $261M.
Equity research analysts estimate Adimmune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adimmune has a P/E ratio of (31.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $242M | XXX | $242M | XXX | XXX | XXX |
| EV (current) | $261M | XXX | $261M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (97.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (25.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 28.4x | XXX | XXX | XXX |
| P/E | — | XXX | (31.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (33.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Adimmune Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Adimmune Margins & Growth Rates
Adimmune's revenue in the last fiscal year declined by (10%).
Adimmune's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Adimmune Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (10%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (1%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Adimmune Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Adimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| Sensorion | XXX | XXX | XXX | XXX | XXX | XXX |
| Milestone Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Acepodia | XXX | XXX | XXX | XXX | XXX | XXX |
| Nkarta | XXX | XXX | XXX | XXX | XXX | XXX |
| Camp4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adimmune M&A Activity
Adimmune acquired XXX companies to date.
Last acquisition by Adimmune was on XXXXXXXX, XXXXX. Adimmune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Adimmune
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAdimmune Investment Activity
Adimmune invested in XXX companies to date.
Adimmune made its latest investment on XXXXXXXX, XXXXX. Adimmune invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Adimmune
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Adimmune
| When was Adimmune founded? | Adimmune was founded in 1965. |
| Where is Adimmune headquartered? | Adimmune is headquartered in Taiwan. |
| How many employees does Adimmune have? | As of today, Adimmune has over 518 employees. |
| Who is the CEO of Adimmune? | Adimmune's CEO is Chi-Hsien Chan. |
| Is Adimmune publicly listed? | Yes, Adimmune is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Adimmune? | Adimmune trades under 4142 ticker. |
| When did Adimmune go public? | Adimmune went public in 2010. |
| Who are competitors of Adimmune? | Adimmune main competitors are Sensorion, Milestone Pharmaceuticals, Acepodia, Nkarta. |
| What is the current market cap of Adimmune? | Adimmune's current market cap is $242M. |
| What is the current revenue of Adimmune? | Adimmune's last fiscal year revenue is $45M. |
| What is the current EV/Revenue multiple of Adimmune? | Current revenue multiple of Adimmune is 5.9x. |
| Is Adimmune profitable? | No, Adimmune is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.